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Tumor suppressor geneparticipate in the development of a wide range of tumors including gliomas, the
main adult primary brain tumors. TGFα soluble form results from the cleavage by the metalloprotease TACE/
ADAM17 of the extracellular part of its transmembrane precursor, pro-TGFα. To gain insights into the
mechanisms underlying TGFα bioavailability, a yeast two-hybrid screen was performed to identify proteins
interacting with pro-TGFα intracellular domain (ICD). DLG1/SAP97 (Discs Large Gene 1 or Synapse Associated
Protein 97) was found to interact with both pro-TGFα and TACE ICDs through distinct PDZ domains. An in
vivo pro-TGFα–DLG1–TACE complex was detected in U251 glioma cells and in gliomas-derived tumor
initiating cells. Interaction between DLG1 and TACE diminished in response to stimulations promoting pro-
TGFα shedding. Manipulation of DLG1 levels revealed dual actions of DLG1 on pro-TGFα shedding, favoring
approximation of pro-TGFα and TACE, while limiting TACE full shedding activity. These results show that
DLG1 participates in the control of TGFα bioavailability through its dynamic interaction with the growth
factor precursor and TACE.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionTGFα is an EGF family member that shares with EGF the tyrosine
kinase receptor EGFR. It is over-expressed in numerous human
cancers of neuroectodermal origin including gliomas, primary tumors
derived from the transformation of astrocytes, neural progenitors or
neural stem cells [1–3]. TGFα over-expression is observed at all steps
of glioma progression, whereas increased levels of both TGFα and
EGFR are associated with high-grade glioma [4,5]. TGFα and EGFR
constitute an important trophic loop for gliomas, through the
promotion of cell proliferation, motility and survival [6,7]. The ﬁnding
of frequent ampliﬁcation of the erbB1 gene, encoding EGFR, as well as
mutations conferring constitutive tyrosine kinase activity to the
receptor in adult gliomas has led most studies to focus on the receptor
[8], and relatively little is known regarding the mechanisms that
control biological availability of TGFα. TGFα is synthesized as a 160 aa
trans-membrane precursor, and the targeting of this precursor to the
membrane has been shown to depend on interactions between the
intra-cellular domain (ICD) of the precursor and the GRASP55 andof Paris 5, 75014 Paris, France.
. Junier).
l rights reserved.syntenin proteins that take place within the secretory pathway [9,10].
Two other pro-TGFα ICD interactors, Naked2 and MAGI-3, appear to
participate in the proper basolateral sorting of the precursor in
polarized epithelial cells [11,12]. The soluble TGFα (50 aa) results from
the proteolytic cleavage of the extracellular domain of the precursor,
once inserted within the membrane, by the metalloprotease TACE
[13]. Adequate targeting and spatial segregation of the precursor to
speciﬁc membrane areas, as well as the amount of growth factor that
is biologically available in either the precursor or the soluble form, are
thus under the control of complex protein interactions. Both the
membrane-anchored TGFα precursor and soluble TGFα bind to and
activate EGFR [1]. The pro-TGFα dominates often over the soluble
form, especially in transformed cells [14,15], and their biological
effects may differ from each other. For example, expression in
pituitary lactotroph cells of a constitutively soluble mutant form of
TGFα triggers proliferation of interstitial cells and pituitary enlarge-
ment, while expression of the wild-type form of pro-TGFα results in
proliferation of lactotroph cells and adenoma [16]. Furthermore,
binding of EGFR by the membrane-bound precursor has been shown
to result in enhanced EGFR signaling [17,18]. These data, associated
with the high conservation among species of the pro-TGFα ICD [19],
led us to postulate a participation of this domain in the regulation of
the bioavailability of the soluble form of the growth factor in glioma
cells, beyond membrane targeting of the precursor. We searched for
265A.-L. Surena et al. / Biochimica et Biophysica Acta 1793 (2009) 264–272proteins interacting with pro-TGFα ICD by yeast two-hybrid assays
using baits corresponding to the intracellular parts of pro-TGFα and
two of its variants. These variants, produced by alternative splicing
and identiﬁed in human keratinocytes, replace the two C-terminal
valines with either 5 (V1) or 4 (V2) amino acids [20]. A bait
corresponding to the ICD of Spitz, the ortholog of TGFα in Droso-
phila, was additionally used. Like TGFα, Spitz binds to the Drosophila
erbB1, DER, and is a gliotrophic factor [21,22]. Among the potential
interacting proteins identiﬁed, we focused our attention on DLG1, also
known as Synapse Associated Protein 97, and previously shown to
interact with TACE [23]. DLG1 is a membrane-associated protein
guanylate kinase homolog (MAGUK) lacking enzymatic activity, and
one of the four human orthologs of the product of the Drosophila
tumor suppressor gene dlg [24]. We report that pro-TGFα, DLG1 and
TACE constitute a tripartite protein complex into which DLG1
participates in the regulation of pro-TGFα shedding.
2. Materials and methods
2.1. Cell culture and transfection
CHOwere cultured in F12 Nutrient Mixture supplemented with 5%
fetal bovine serum and COS7 cell lines and U251 human cell line were
cultured in DMEM supplemented with 10% fetal bovine serum
(Invitrogen, Life Technologies). Expression of the wild-type form of
EGFR in U251 cells was veriﬁed by immunoblotting (data not shown).
Tumor initiating cells were derived from surgical biopsies of adult
high-grade gliomas performed in Sainte-Anne Hospital, with the
informed consent of the patients [25]. Surgical biopsies were treated
with 0.25% trypsin in 0.1 mM EDTA prior trituration through a ﬁre-
polished Pasteur pipette. The cell suspension was puriﬁed onto a 22%
Percoll gradient, and thereafter plated in 75 cm2 tissue culture ﬂasks
at 2500–5000 cells/cm2 in DMEM:F12 (1:1) medium containing N2,
G5 and B27 (Invitrogen). After a delay of 22 days in culture, spheres
bloomed from clusters of adherent cells and detached in the medium.
They were collected and dissociated in single cells suspension each
week with a renewal of 2/3 of their culture medium. Characterization
included self-renewal (up to 3 years), clonal abilities, cell surface
proﬁling (the cells are CXCR4+, NCAM+, CD15/SSEA1+, CD133low), and
formation of tumors after intracerebral grafting. Cell transfection was
achieved using either the Lipofectamine reagent (Invitrogen, France)
or the Nucleofector device with the cell transfection kit and according
to the supplier's instructions (Amaxa biosystems, Germany).
2.2. cDNA and siRNA constructs
cDNAs encoding pro-TGFα variants were derived by site directed
mutagenesis from the human pro-TGFα cDNA [26] using the following
primers pairs: forward, ATA ATG AAT TCG GAG GTC ACT GCT GCC AG,
and reverse V1, GCG GCC GCT CAG TAT AGT CGA CAT CCT GTT TCT G, or
reverse V2, CTG CAG TCA TCC TAG GGT GGC TGT TTC TGA GTG GC. GST
fusion constructswere produced by subcloning the cDNAs encoding the
ICD of pro-TGFα or its variants V1 and V2 into the pGEX-4T1 vector (GE
Healthcare, France). Full-length pro-TGFα cDNA was cloned into
pcDNA3 (Invitrogen, France). EGFP-DLG1 expression vectors, and GST-
TACE fusion protein with the GST tag in N-terminal position were
obtained as described [23]. Transient DLG1 knockdown was achieved
using a siRNA sequence purchased fromSIGMA (France), corresponding
to nt 2551–2569 of hDLG1 cDNA (NM-004087) (Sigma-Proligo, France).
The corresponding scrambled siRNA, and the AlexaFluor488-tagged
negative control obtained from Qiagen (France), were used as controls.
2.3. Antibodies
Anti-DLG1 (Anti-SAP97, VAM-PS005) was from Stressgen, and
anti-TACE from Santa-Cruz (sc-6416, TEBU, France). Anti-pro-TGFαICD was a gift from Dr LE Gentry (Toledo, Ohio, rabbit polyclonal
antibody 1296 raised against pro-TGFα aa 137–151, [27]). Antibody
directed against the extracellular domain of pro-TGFα was from
Santa-Cruz (sc-36, TEBU, France).
2.4. Yeast two-hybrid screen
The intra-cellular domain of human pro-TGFα (aa 120–160) and its
two variants (V1 aa 122–163, V2 aa 122–162) was sub-cloned in pB27
and used as baits in L40 yeast co-transformed with a human placental
cDNA library. Two-hybrid screens were performed as described
[28,29]. Human and Drosophila constructs were used as baits to
screen a random-primed human placenta or a Drosophila embryo
cDNA library, respectively. Both libraries were constructed into pP6,
derived from the original pGADGH plasmid [30]. An average of
87 million clones (8-fold the complexity of the library) was screened
for each bait using a mating approach with L40-Gal4 (mata) and Y187
(matα) yeast strains as previously described [28,31]. His+ colonies
were selected on medium lacking tryptophan, leucine and histidine,
supplemented with 5 mM (pro-TGFα, variant V1 and Spitz) or 2 mM
(variant V2) 3-aminotriazole to reduce bait autoactivation.
2.5. In vitro binding assays
Using the plasmids pcDNA3-HA-DLG1 encoding aa 126–654
hDLG1, pcDNA3-HA-DLG1-PDZ2 or PDZ3 encoding the second (aa
316 to 406) or third (aa 462 to 547) PDZ domain of DLG1, respectively,
[35S]Cys-Met-radiolabeled proteins were synthesized in a coupled in
vitro transcription/translation reaction (TnT T7, Promega). Radiola-
beled proteins (2 μl out of 50 μl of translation reaction) were incubated
with 1 μg of GST-fusion protein adsorbed on glutathione-Sepharose
beads for 3 h at 4°C in 10mMTris HCl pH 7.4, 1 mMMgCl2, 1% Triton X-
100, 50 mM NaCl, 0.1% BSA. Proteins were resolved by SDS-PAGE, and
radiolabeled DLG1 was detected in a Packard Instant Imager.
2.6. Immunoblotting and immunoprecipitation
U251 cells were seeded at 15 ·106 cells/100 mm diameter dish,
tumor initiating cells at 5–10·106 cells/15 ml. Both cell types were
cultured for 2 days then treated for 90 min with 30 μM of the
metalloprotease inhibitor GM6001 (Millipore, France) in order to
prevent pro-TGFα shedding prior to lysis. Lysis was performed in the
following buffer: 1 mM sodium pyrophosphate, 50 mM β-glyceropho-
sphate, 25 mM PIPES pH 6.8, 1.5 mM EGTA, 0.5 mM EDTA, 1 mM
sodium orthovanadate, 5 mg/ml leupeptine, 5 mg/ml pepstatine,
5 mg/ml aprotinin, 1 mM PMSF, 1% Triton X-100, 10 μM GM6001). The
cell lysates (1 mg protein) were incubated for 3 h at 4°C with either
2 μg anti-DLG1, or 1 μl anti-pro-TGFα or 5 μg anti-TACE. Immunopre-
cipitations from stimulated cells and serum-starved cells were carried
out with 500 μg protein. Immune complexes were captured with
protein G-sepharose beads, and resolved by 4–12% SDS-PAGE. The
proteins were visualized by immunoblotting with anti-SAP97 (1/
2500), anti-TACE (1/250) or anti-TGFα-ECD (1/250) antibodies.
Densitometric analysis was achieved using the Quantity One software
(Biorad, France). Endoglycosidase H (EndoH) treatment was per-
formed according to the manufacturer's instructions (Biolabs, France)
in lysis buffer, using RNase B as a positive control.
2.7. Immunocytochemistry
Immunocytochemical procedures were as described [32]. Immu-
noﬂuorescence was observed with a ﬂuorescent microscope (Eclipse
E800, Nikon, USA). Images were acquired on a digital still camera
(DXM 1200, Nikon, USA) using Lucia software (Laboratory Imaging,
Ltd.). For confocal immunoﬂuorescence, samples were observed using
a Leica TCS SP2 confocal microscope. Two lasers were used depending
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objectives, with the 1.25 and 1.32 numerical aperture lenses,
respectively (Leica, Germany). The pinhole was set on the airy spot
and the images were acquired in a sequential scan mode for double
immunoﬂuorescent labeling. The images were prepared using Adobe
Photoshop software (Adobe Systems, San Jose, CA).
2.8. TGFα assay in culture media
Conditioned medium from U251 cells was collected at 12 or 18 h
after transfection. 24 h post-transfection, COS7 cells were serum starved
for 1 h, then exposed for 30 min to serum-free medium±500 nM PMA.
TGFα levels were assayed using an anti-humanTGFα sandwich ELISA (R
and D systems, France) following the manufacturer's instructions.
2.9. Statistical analyses
Statistical analyses were done using ANOVA followed by a Fisher
test, the level of signiﬁcance was set at pb0.05, and results are shown
as mean±SEM.
3. Results
3.1. Identiﬁcation of a direct interaction between pro-TGFα ICD and DLG1
PDZ domains by yeast two-hybrid and in vitro assays
A yeast two-hybrid screen of a human placental cDNA library was
performed using as baits the ICD of pro-TGFα and of its two variantsFig.1. (A, B) Identiﬁcation of DLG1/SAP97 as a partner of pro-TGFα in yeast two-hybrid assay.
used in yeast two-hybrid screen correspond to the intra-cellular domains of pro-TGFα and its
a human placental library and encoding DLG1. A total of 30 independent clones were obtained
MAGUK familymember composed of three PDZ domains, an src homology 3 domain (SH3), an
of pro-TGFα is required for its interaction with the second and third PDZ domains of DLG1 in
was incubatedwith GST-pro-TGFα ICD fusion protein, GST-V1 ICD or GST-V2 ICD. Bound prote
vitro translated [35S]met-cys-labeled hDLG1 PDZ2 (aa 316–406) or PDZ3 domains (aa 462–(V1, V2, Fig. 1A). The screen yielded 141 positive clones for the bait
corresponding to the ICD of pro-TGFα, 239 clones for V1 and 75 clones
for V2. Sequencing of the clones recovered using pro-TGFα as a bait
showed that the majority of them contained cDNA encoding proteins
with PDZ (PSD-95/DLG/ZO-1) domains, whereas none of those
recovered using the ICDs of V1 and V2 as baits encoded PDZ-
containing proteins. This ﬁnding is consistent with the presence only
in the pro-TGFα ICD of a consensus motif E-S/T-X-V/I/L (X=any amino
acid) recognized by class I PDZ domains [33]. Fifteen of the positive
clones encoded part of MAGI-3, a protein recently found to interact
with pro-TGFα [11], and thirty other clones encoded parts of the
human DLG1 protein [34]. DLG1 is a 926-amino acid (aa) membrane-
associated protein, member of the family of scaffold proteins with
guanylate kinase domains (MAGUK). It possesses three PDZ domains,
an SH3 (src homology 3) domain and a guanylate kinase-like domain
without enzymatic activity [35]. The clones were of various lengths
encompassing aa 83 to 709 (Fig. 1B). All contained the sequence
encoding aa 316 to 406 (Fig. 1B) corresponding to the second PDZ
domain (PDZ2). None of the clones recovered with V1 and V2 ICDs as
baits contained any DLG1 part. DLG, the Drosophila ortholog of DLG1
was not recovered when using as bait the Spitz ICD, which does not
possess a PDZ-binding motif. GST fusion proteins were used to
validate and further characterize the interaction between pro-TGFα
ICD and DLG1. In GST pull-down assays, [35S]met-cys-labeled hDLG1
([35S]DLG1) was retained by GST-proTGFα ICD (Fig. 1C). On the other
hand, neither GST-V1 nor GST-V2 ICDs retained [35S]DLG1 (Fig. 1C),
suggesting that the PDZ domain-binding motif at the C-terminal end
of pro-TGFα ICD is critical to interaction with DLG1, probably through(A) Representation of pro-TGFα and its two C-terminal end variants, V1 and V2. The baits
variants. (B) Schematic representation of the clones yielded in the two-hybrid screen of
, all encompassing the coding region for the second DLG1 PDZ domain (PDZ2). DLG1 is a
d a guanylate kinase domain (GK) without enzymatic activity. (C, D) The C-terminal end
GST-pull down assays. (C) In vitro translated [35S]met-cys-labeled hDLG1 (aa 216–654)
ins were pulled by glutathione-sepharose beads and revealed by autoradiography. (D) In
547) were incubated with either GST-pro-TGFα ICD or GST-V2 ICD fusion proteins.
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hybrid screen included the sequence encoding the PDZ2 domain of
DLG1, only 20 of them also included sequences encoding the PDZ3
domain while only 7 of them additionally contained sequences
encoding PDZ1. These data suggest that PDZ2 domain of DLG1 is
critical for DLG1 interaction with pro-TGFα ICD. As expected, V2 ICD
did not interact with either of these PDZ domains (Fig. 1D). On the
contrary, GST pull-down assays showed that either the PDZ2 or PDZ3
domain of DLG1 couldmediate interactionwithpro-TGFα ICD (Fig.1D).
3.2. DLG1 interacts with both the pro-TGFα and the TACE ICD
DLG1 has been reported to interact with the ICD of TACE, the
metalloprotease responsible for the shedding of the extracellular
domain of pro-TGFα [23]. Using GST pull-down assays, we conﬁrmed
that DLG1 interacts with the ICD of TACE (Fig. 2A), and that this
interaction was mediated exclusively by the DLG1 PDZ3 domain (Fig.
2B). In contrast, no interaction between TACE and pro-TGFα ICDs was
observed in GST pull-down experiments (data no shown). The ability
of DLG1 to interact with both pro-TGFα and TACE ICDs when both
proteins are present was tested using a HA-tagged DLG1 protein.
Immunoprecipitation with anti-HA antibodies retrieved both GST-
TACE and GST-pro-TGFα ICDs, indicating thus that TACE and TGFα
ICDs do not compete for binding to DLG1 (Fig. 2C). Taken altogether,
these data suggested that DLG1 might link pro-TGFα and TACE.
3.3. Formation of a tripartite complex between pro-TGFα, DLG1 and TACE
The human glioma cell line U251, endowed with an autocrine
TGFα/EGFR trophic loop [36], was used to determine whether the
endogenous pro-TGFα, DLG1 and TACE proteins interact in vivo to
form a tripartite complex. TACE is synthesized as an immature
zymogen containing an inhibitory N-terminal pro-domain. Cleavage
of the pro-domain by a furin-like protease in the trans-Golgi yields in
the mature form of TACE [37,38]. Immunoblotting showed that U251Fig. 2. (A, B) TACE intra-cellular domain interacts with DLG1 via its PDZ3 domain in
vitro. (A) In vitro translated [35S]met-cys-labeled hDLG1 (aa 216–654) was incubated
with GST-pro-TGFα ICD, GST-TACE ICD, or GST. Bound proteins were revealed by
autoradiography. (B) In vitro translated [35S]met-cys-labeled hDLG1 PDZ2 (aa 316–406)
or PDZ3 domains (aa 462–547) were incubated with GST-TACE ICD. (C) TACE and pro-
TGFα ICDs do not compete for interaction with DLG1. HA-DLG1 was incubated with
either GST-TACE, or GST-pro-TGFα ICDs or both fusion proteins.cells expressed DLG1 and the immature (98 kDa) and mature (80 kDa)
forms of TACE (Fig. 3A, lanes 1 and 2). TGFα expressionwas veriﬁed by
ELISA and ranged between 15 and 90 pg/mg total proteins.
Immunoprecipitation was carried out using antibodies directed
against either DLG1, or the TACE or pro-TGFα ICD. Immunoprecipita-
tion with DLG1 antibodies, followed by TACE immunoblotting yielded
two bands corresponding to the expected molecular weights of the
immature and mature forms of TACE with a net preponderance of the
mature over the immature form (Fig. 3A, lane 3). Conversely,
immunoprecipitation with TACE antibodies, followed by DLG1
immunoblotting resulted in the detection of DLG1 (Fig. 3A, lane 4).
To determine whether pro-TGFα, DLG1 and TACE constitute a
tripartite association in vivo, we carried out immunoprecipitations
with antibodies directed against the pro-TGFα ICD followed by the
detection of TACE and DLG1 by immunoblotting. U251 cells were
treated with the metalloprotease inhibitor GM6001 prior to lysis in
order to prevent shedding of pro-TGFα [23,39]. In accordancewith the
levels of pro-TGFαmeasured by ELISA in U251 cells, the precursor was
not detectable by direct immunoblotting of the cellular protein lysate
(Fig. 3B, lane 1). Following immunoprecipitation, pro-TGFα was
readily detected with antibodies directed against its extracellular
domain (Fig. 3B, lane 2). Speciﬁcity of the anti-pro-TGFα ICD
antibodies used for the immunoprecipitation step was ascertained
by the lack of immunoreactive signal when the antibodies were
preadsorbed with GST-TGFα ICD fusion protein (Fig. 3B, lane 3). Pro-
TGFα ICD immunoprecipitation resulted in detection of DLG1 (Fig. 3B,
lane 4), as well as the mature form of TACE, and at a much lower level
the immature form of TACE (Fig. 3B, lane 5).We additionally sought for
pro-TGFα, DLG1 and TACE in human tumor initiating cells derived
from a subset of high-grade gliomas, the neuro-glial malignant tumors
[25]. DLG1 and TACE expressions were evidenced by immunoblotting
(Fig. 3C, lanes 1 and 2), and pro-TGFα by ELISA using tumor initiating
cells lysates (36 pg/mg protein total). In addition, we detected by
immunoblotting the expression of EGFR by these cells (not shown).
Immunoprecipitation assays with antibodies directed against DLG1
(Fig. 3C, lane 3), TACE (Fig. 3C, lane 4) and pro-TGFα ICD (Fig. 3C, lanes
5 and 6) demonstrated that these three proteins form a tripartite
complex in vivo in tumor initiating cells derived from high-grade
glioma, as well as in U251 glioma cells.
The preponderance of the mature form of TACE in all immuno-
precipitations, and the known limited amount of immature TACE
reaching the cell membrane [37,38] indicated that the physical
approximation of the three proteins takes place at the cell membrane
and/or in the late secretory pathway. In addition, we treated the cell
lysates and the immunoprecipitates performed with anti-TGFα
antibodies with EndoH. Indeed, pro-TGFα has been reported to be
highly glycosylated in the early secretory pathway and to loosemost of
its sugars upon progression in the late secretory pathway [9,40–42].
We thus reasoned that if the physical approximation between the
proteins occurs at early steps of the secretory pathway, we should
observe a shift in the apparent pro-TGFα MW. EndoH treatment did
not modify TGFα MW (Fig. 3D), thus further indicating that the
interaction between pro-TGFα, DLG1 and TACE occurs at the cell
membrane and/or in the late secretory pathway.
3.4. Immunocytochemical localization of DLG1, pro-TGFα and TACE
The demonstration that DLG1 interacts with both pro-TGFα and
TACE led us to postulate an involvement of this protein complex in the
control of pro-TGFα extracellular domain shedding, a step crucial in
the mitogenic and transforming effects of TGFα [1]. Immunocyto-
chemical detection of the three proteins in U251 cells showed co-
localizations of pro-TGFα and TACE, pro-TGFα and DLG1, and TACE
and DLG1 (Fig. 4A). The consequences of DLG1 expression on pro-
TGFα cellular localization were explored using CHO cells transfected
with pro-TGFα and EGFP-DLG1 expression plasmids. Expressions of
Fig. 3. Pro-TGFα, DLG1 and TACE form a tripartite complex in U251 cell line and in tumor initiating cells derived from high-grade glioma. (A) Co-immunoprecipitation of DLG1 and
TACE in U251 cells. DLG1 and the immature (i) andmature (m) forms of TACEwere detected in U251 cells by direct immunoblotting (IB, lanes 1 and 2). Both TACE formswere detected
in DLG1 immunoprecipitate (IP, lane 3). Likewise, DLG1 was detected in TACE immunoprecipitate (lane 4). ⁎ indicates non-speciﬁc signal. (B) Detection of a pro-TGFα–DLG1–TACE
complex in U251 cells. Immunodetection of pro-TGFα in U251 cells with antibodies directed against the precursor extra-cellular domain before (lane 1) and after (lane 2)
immunoprecipitation with anti-pro-TGFα ICD antibodies. Pro-TGFα signal is suppressed when using in immunoprecipitation anti-pro-TGFα ICD antibodies pre-absorbed on GST-
pro-TGFα fusion protein (lane 3). DLG1 (lane 4) and TACE (lane 5) are detected in pro-TGFα ICD immunoprecipitates. (C) Detection of a pro-TGFα-DLG1-TACE complex in high-grade
glioma tumor initiating cells. DLG1 (lane 1) and TACE (lane 2) are expressed in high-grade glioma tumor initiating cells (lanes 1 and 2). Co-immunoprecipitation of DLG1 and TACE in
high-grade glioma tumor initiating cells (lanes 3 and 4). ⁎ indicates non-speciﬁc signal. Co-immunoprecipitation of pro-TGFα, DLG1 and TACE in high-grade glioma tumor initiating
cells (lanes 5 and 6). (D) Insensitivity of pro-TGFα to Endo H treatment. The immature forms of pro-TGFα being known to be highly glycosylated in the compartments of the early
secretory pathway, we veriﬁed the sensitivity of the detected pro-TGFα form to EndoH treatment. As expected, EndoH reduced the apparent MWof the positive control RNase B (left
panel, lane 2 versus lane 1). On the opposite, it was without effect on the apparent MW of pro-TGFα detected in either the whole cell lysates (lane 4 versus lane 3) or the TGFα-
immunoprecipitates (lane 6 versus lane 5). ⁎This band corresponds to the anti-proteases added to the reaction solution.
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Immunocytochemical detection of pro-TGFα, using an antibody
directed against the extracellular domain of the precursor, revealed
a partial co-localization of DLG1 and pro-TGFα (Fig. 4B), and the
distribution of TGFα immunoﬂuorescent signal was similar in cellsFig. 4. (A) Immunoﬂuorescent detections of TGFα, TACE and DLG1 in U251 cells. First line
Bar=20 μm. Right-most panel: overlay of confocal microphotographies showing co-localizat
immunoﬂuorescent labelings of TGFα (green) and DLG1 (red) in U251 cells. Bar=20 μm. Ri
TGFα and DLG1 in cellular protrusions in zones of cell–cell contacts. Bar=5 μm. Third line
Bar=20 μm. Right-most panel: overlay of confocal microphotographies showing co-localizati
immunoﬂuorescent analysis of TGFα (red) in CHO cells transfectedwith pro-TGFα and EGFP-D
asterisk labels a cell singly transfected with pro-TGFα. Bar=20 μm. (C) Down-regulation of D
DLG1 mRNA (DLG1 siRNA) or scrambled siRNA. DLG1 down-regulation was veriﬁed usin
detection of DLG1 in U251 transfected with scrambled siRNA or DLG1 siRNA. Bar=20 μm. (
immunoblotting with TGFα antibodies. Right-panel illustrates TGFα (green) or TACE (red) im
normal DLG1 expression as depicted in A. Bars=10 μm. (E) DLG1 down-regulation using DL
TACE and pro-TGFα upon DLG1-down-regulation.singly transfected with pro-TGFα (Fig. 4B). Similarity of the patterns of
TGFα and TACE immunocytochemical stainings in DLG1 siRNA-
transfected U251 cells (Fig. 4D), and EGFP-DLG1-transfected U251
cells as compared to controls (Fig. 5A and B), indicated that DLG1 did
not affect the intra-cellular trafﬁcking of the proteins of interest.: double immunoﬂuorescent labelings of TGFα (green) and TACE (red) in U251 cells.
ions of TGFα and TACE at the edge of the cell (arrow). Bar=10 μm. Second line: double
ght-most panel: overlay of confocal microphotographies illustrating co-localizations of
: double immunoﬂuorescent labelings of DLG1 (green) and TACE (red) in U251 cells.
ons of DLG1 (green) and TACE (red) in zones of cell–cell contacts. Bar=5 μm. (B) Confocal
LG1 expression plasmids. The arrow points to a cell transfectedwith both plasmids. The
LG1 expression in U251 cells. U251 cells were transfected with siRNA directed against
g immunoblotting with anti-DLG1 and anti-actin antibodies, and immunoﬂuorescent
D) Lack of decrease in pro-TGFα levels upon DLG1 down regulation was veriﬁed using
munolabelings, which were similar in DLG1 siRNA transfected U251 cells and cells with
G1 siRNA inhibited TGFα release in culture medium. F. Decreased interaction between
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shedding
We determined the effects of DLG1 down-regulation using siRNA
and U251 cells (Fig. 4C). The amount of TGFα released in the culturemedium was assessed using ELISA 3 days after transfection.
Inhibition of DLG1 levels by 75% (Fig. 4C) resulted in a reduced
level of TGFα assayed in the culture medium (55.3 and 58.4% of
control in two independent experiments, Fig. 4E), while the
amounts of TGFα detected slightly increased as expected (Fig. 4D).
Fig. 5. Consequences of DLG1 over-expression on the cleavage of pro-TGFα. (A) Immunoﬂuorescent detection of TGFα (red) in EGFP-DLG1-transfected U251 cells (green) was
achieved with antibodies directed against the extra-cellular domain of the precursor. A similar repartition of the TGFα immunoﬂuorescent signal was observed regardless of DLG1
expression. (B) Immunoﬂuorescent detection of TACE (red) in EGFP-DLG1-transfected U251 cells (green). A similar repartition of TACE immunoﬂuorescent signal was observed
regardless of DLG1 expression. Bar=20 μm. (C) Left panel: U251 cells were transfected with expression plasmids encoding either EGFP tagged DLG1 (EGFP-DLG1) or a mutant DLG1
lacking the PDZ3 domain (EGFP-DLG1ΔPDZ3). The cells were maintained in 5% FBS medium. DLG1 overexpression inhibited TGFα release in the culture medium. Right panel: COS7
cells were co-transfected with pro-TGFα and EGFP-DLG1 or EGFP-DLG1ΔPDZ3 expression vectors. One day post-transfection, the cells were placed in serum-free medium prior to be
incubated 30 min in medium supplemented or not with 500 nM PMA. DLG1 over-expression inhibited both basal and PMA-stimulated release of TGFα in the culture medium. mean
±SEM, n=3. ⁎pb0.05. (D) EGFP-DLG1 overexpression did not modify pro-TGFα levels, as compared to EGFP-DLG1ΔPDZ3 and EGFP-DLG1-transfected U251 cells.
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fected U251 cells showed the usual predominance of the mature
form of TACE over its immature form in control conditions, and
diminished levels of TACE in DLG1 siRNA conditions. Altogether,
these results are consistent with a role for DLG1 as a scaffold protein
promoting the approximation of pro-TGFα and TACE.
We then used expression plasmids to examine the consequences
of DLG1 over-expression on pro-TGFα shedding. U251 cells were
transfected with expression plasmids encoding full length DLG1, or
as control a DLG1 mutant lacking the PDZ3 domain (DLG1ΔPDZ3),
PDZ3 being required for the interaction between TACE and DLG1
(Fig. 2B). The amounts of TGFα were unchanged in the transfected
cells (Fig. 5D). Unexpectedly, DLG1 over-expression inhibited by 30%
the level of TGFα in the culture medium as compared to control
conditions (Fig. 5C, left panel). The results show that opposite
modulations of DLG1 levels result both in inhibition of TGFα release
into the medium, suggesting that DLG1 control of pro-TGFα
shedding extends beyond simple scaffolding of the precursor and
its shedding enzyme. We therefore examined the effects of DLG1
over-expression under conditions that stimulate pro-TGFα extra-
cellular domain cleavage including addition of serum, protein kinase
C activation or treatment with TGFα itself [43]. Since the transfectionprocedure sensitizes U251 cells to serum deprivation, we repeated
the DLG1 over-expression experiments using COS7 cells that express
TACE and DLG1 in a constitutive manner [23]. COS7 cells were co-
transfected with either pro-TGFα and EGFP-DLG1 or EGFP-
DLG1ΔPDZ3 expression vectors. DLG1 over-expression effects on
TGFα release were then examined under basal conditions in serum
free medium±phorbol 12-myristate-13-acetate (PMA). PMA stimula-
tion resulted in a doubling of the amount of TGFα detected in the
culture medium (Fig. 5C, right panel). Under control conditions, DLG1
over-expression inhibited pro-TGFα shedding by half (Fig. 5C, right
panel). The inhibitory effect of DLG1 was maintained under PMA-
stimulation albeit at a reduced level (30%) similar to the one
observed in U251 cells maintained in serum containing medium (Fig.
5C, right panel).
3.6. TACE and DLG1 interaction is a regulated process
Serum-deprived U251 cells were stimulated for 30 min with
serum, PMA or TGFα prior to lysis. PMA has been reported to stimulate
TACE degradation in DRM cells [44]. In U251 cells, immunoblotting of
serum, TGFα and PMA-stimulated cells showed unchanged levels of
the immature and mature forms of TACE in stimulated conditions as
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extracted from control and stimulated cells were submitted to
immunoprecipitation assays using DLG1 antibodies. The amount of
mature TACE retained by DLG1 diminished in serum-, PMA- and
TGFα-stimulated cells as compared to control non-stimulated condi-
tions, to 63.3±12.5%, 57.5±13.7% and 45.1±14.0% of control levels,
respectively (mean±SEM, n=3, Fig. 6A and B). Likewise, immunopre-
cipitation assays using TGFα antibodies resulted in a decreased
amount of DLG1 retained by TGFα in PMA- and TGFα-stimulated cells
as compared to control non-stimulated conditions (Fig. 6C). Taken
altogether, our data suggest that the scaffold role of DLG1 towards
TACE and pro-TGFα is associated with an inhibitory control limiting
the access of the enzyme to its cleavage site, which is alleviated under
stimulated conditions.Fig. 6. Signals promoting pro-TGFα shedding regulate TACE-DLG1 and pro-TGFα–DLG1
interactions. (A) U251 cells were maintained in serum-free medium with or without
serum (10%), PMA (500 nM) or TGFα (50 ng/ml). In stimulated cells, the amounts of
TACE detected in DLG1 immunoprecipitates were reduced to 40% of the control levels.
Example of three independent experiments. (B) Determination of the ratio of TACE/
DLG1 signals was determined by densitometric analysis. Results are expressed as % of
control (mean±SEM, n=3). (C) The amount of DLG1 detected in TGFα immunopreci-
pitates of PMA- and TGFα-stimulated cells was reduced as compared to control. Note
the decreased pro-TGFα signal detected in the presence of PMA, one the most potent
stimulator of pro-TGFα shedding.4. Discussion
We describe a novel interaction between the PDZ-containing
protein DLG1 and pro-TGFα that participates in the control of the
release of the soluble form of TGFα. In addition, we provide for the
ﬁrst time the identiﬁcation of a protein complex sufﬁcient for a
functional TGFα/EGFR trophic loop in tumor initiating cells derived
from high-grade gliomas, i.e. EGFR, its ligand TGFα, and TACE.
Findings using yeast two-hybrid assays and in vitro assays with
recombinantmolecules were conﬁrmed using cells that express all the
partners of the complex in an endogenous manner. Microscopic
visualization of pro-TGFα and DLG1 in heterologous systems as well as
naive cells showed that both proteins could co-localize within the
cytoplasm and at the cell membrane. TACE is synthesized in an
immature form and the mature enzyme results from the cleavage of a
pro-domain by a furin-like protease in the trans-Golgi [37,38]. The
preponderance of the mature form of TACE in all immunoprecipita-
tions performed in the present study, and the identiﬁcation of the full
processed form of pro-TGFα in the immunoprecipitates indicate that
interaction between pro-TGFα, DLG1 and TACE occurs at the cell
membrane and/or in the late secretory pathway.
The interaction between pro-TGFα and DLG1 depends from the
four C-terminal residues of pro-TGFα, which forma consensus-binding
motif for class I PDZdomains [33]. Of note, only a fraction of the 41PDZ-
containing proteins known to be expressed from the placental cDNA
library used in the two-hybrid screen have been found with pro-TGFα
as bait. Most importantly, the numerous screens using the same library
with baits bearing a PDZ binding motif alike to pro-TGFα have yielded
in PDZ-containing proteins different from the ones identiﬁedwith pro-
TGFα (EF, unpublished results). These results are in agreement with
recent works showing that the selectivity of recognition between PDZ
domains and PDZ consensus motifs does not follow a strict logic of
classes [45,46]. Shedding of EGFR-ligands takes place in Drosophila as
in mammals but is ensured by different enzymes, the rhomboid-type
proteases [47]. Our two-hybrid screen of a Drosophila adult brain and
embryo cDNA library with the ICD of Spitz, the ortholog of TGFα, did
not yield DLG among the preys ([28] complete results can be seen at
http://pim.hybrigenics.com). This further indicates that the remarkable
conservation of the EGFR-signaling pathway across evolution is
achieved with varying molecular actors [21].
Our results show that the carboxyl extremity of pro-TGFα, which
mediates binding to PDZ domains, is critical for its integration into a
complex that includes the protease necessary for shedding of the
mature growth factor. This emphasizes the central role of the PDZ
binding motif of pro-TGFα for proper processing of the precursor,
from its progress through the secretory pathway to the release of its
soluble form, once the precursor is inserted at the membrane.
Members of the MAGUK family such as DLG1 contain PDZ domains
that allow them to interact with different proteins. They are primarily
known as adaptor molecules, gathering functionally related proteins
at specialized cellular structures including neuronal post-synaptic
densities and epithelial cell junctions [35]. The ability of DLG1 to bind
both pro-TGFα and TACE through two distinct PDZ domains supports
the idea of a scaffold function for DLG1, allowing the spatial
approximation of two proteins highly related at the functional level,
an enzyme and its substrate. In accordance with such a scaffold role
for DLG1, we observed reduced levels of soluble TGFα in the culture
medium of U251 cells following transient knockdown of DLG1
expression with siRNA. Our results show that over-expression of
DLG1 also, surprisingly, reduces the amount of soluble TGFα released
in the cellular medium. This suggests that the proper function of this
tripartite complex is dependent on tight control over the levels of its
components. The lack of enzymatic activity in DLG1 [48] suggests that
its inhibitory effect on pro-TGFα shedding arises from a steric
obstruction that limits the access of TACE to its substrate. The fact
that the association between DLG1 and TACE, and DLG1 and pro-TGFα
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(i.e. PKC stimulation and TGFα itself) strongly supports such a
possibility. Variations in the rate of DLG1 phosphorylation might
underlie the stability of its association with TACE and pro-TGFα, since
all stimuli used in the present study have the potential to trigger
protein phosphorylation [43,49]. Serine and threonine phosphoryla-
tions within the TACE ICD may promote TACE maturation [50], but
have not been shown to affect PMA-, serum- or growth factor-
stimulated pro-TGFα shedding [49].
Our results, together with data in the literature, favor the idea that
TACE, DLG1 and pro-TGFα are engaged in a dynamic equilibrium and
suggest the following model. Under control conditions, the bound
forms of the proteins predominate, allowing DLG1 to sustain its
classical scaffold role, clustering TACE and its substrate, while limiting
the accessibility of the enzyme to its cleavage site, possibly through
steric obstruction. In response to stimulations, the equilibrium is
displaced towards the free forms, allowing full access of TACE to its
substrate. The control exerted by DLG1 on pro-TGFα shedding would
thus allow the rapid mobilization of the growth factor when required,
while limiting the deleterious consequence of a prolonged activation
of the EGFR-signaling pathway through excessive release of its ligand.
Deregulations of EGFR-signaling in time and space may have
profound consequences on the stability of the differentiated mature
phenotype of neuroectodermal cells such as astrocytes, one of the cell
types at the origin of gliomas [32], as well as epithelial cells [51].
Furthermore, sustained EGFR-signaling is well known to promote the
cancerous transformation of epithelial cells [1]. Regulation of DLG1
levels also appears to be critical to cell transformation. The papilloma
virus oncoprotein E6 targets DLG1 for proteasome degradation [52],
and the binding of HTLV-1 Tax oncoprotein to DLG1 prevents the
formation of an important cell cycle suppression signal, the adeno-
matous polyposis coli:DLG complex [53,54]. In addition, down
regulation of the DLG1 protein is associated with dlg1 somatic
mutations in mammary carcinomas [55], and these tumors frequently
over-express TGFα, which acts as an oncogene in these tumors [1,56].
The present study establishes a central role for the scaffold protein
DLG1 in the release of the soluble form of TGFα by the cleavage
enzyme TACE. TACE is a hub in the EGFR-driven signaling pathway,
which controls cell functions deregulated in transformed cells, i.e.
proliferation, apoptosis and migration. EGFR integrates autocrine and
paracrine signals provided by its own ligands, but also signals-derived
from GPCR activation, which stimulates the shedding of the soluble
form of EGFR ligands and subsequent activation of the receptor [57].
Within this frame, perturbations of the interactions between pro-
TGFα, DLG1 and TACE may have signiﬁcant consequences on the
control exerted by DLG1 on pro-TGFα shedding by TACE, and hence on
the activity of the EGFR signaling pathway.
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